Bilsimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods. Biologic drugs can be patented, but once the patents expire, biosimilars can enter the market.
Are biosimilars> priced similarly to generics? According to Ana Nicholls, healthcare analyst at The Economist Intelligence Unit, the answer is no:
“Given the lower levels of competition in the biosimilars market, the copies tend to be priced at just 20-30% below the original drugs, compared with around 90% below for traditional generics.”